Holen Sie sich die Stockscreener-App
14.46
0.00%
0.00
Handel nachbörslich:
14.46
Schlusskurs vom Vortag:
$14.46
Offen:
$14.45
24-Stunden-Volumen:
4.93M
Relative Volume:
0.98
Marktkapitalisierung:
$4.54B
Einnahmen:
$634.21M
Nettoeinkommen (Verlust:
$-27.11M
KGV:
-163.39
EPS:
-0.0885
Netto-Cashflow:
$29.85M
1W Leistung:
+0.00%
1M Leistung:
+0.63%
6M Leistung:
+72.76%
1J Leistung:
+109.57%
1-Tages-Spanne:
$14.45
$14.46
1-Wochen-Bereich:
$14.45
$14.47
52-Wochen-Spanne:
$5.51
$14.48
Amicus Therapeutics Inc Stock (FOLD) Company Profile
Firmenname
Amicus Therapeutics Inc
Sektor
Branche
Telefon
(609) 662-2000
Adresse
47 HULFISH STREET, PRINCETON, NJ
Compare FOLD vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FOLD
Amicus Therapeutics Inc
|
14.46 | 4.54B | 634.21M | -27.11M | 29.85M | -0.0885 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Amicus Therapeutics Inc Stock (FOLD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-22 | Herabstufung | Jefferies | Buy → Hold |
| 2025-12-29 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-12-22 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-12-17 | Eingeleitet | Citigroup | Buy |
| 2025-09-18 | Hochstufung | Needham | Hold → Buy |
| 2025-07-17 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-13 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-09-06 | Eingeleitet | Jefferies | Buy |
| 2024-05-30 | Eingeleitet | Wells Fargo | Overweight |
| 2024-05-14 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-12-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-04-13 | Fortgesetzt | Goldman | Neutral |
| 2022-01-14 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-11-15 | Hochstufung | Stifel | Hold → Buy |
| 2021-09-30 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-07-19 | Fortgesetzt | BTIG Research | Buy |
| 2021-05-27 | Eingeleitet | Needham | Hold |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-04-14 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2021-03-02 | Eingeleitet | Stifel | Hold |
| 2021-02-12 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2021-02-12 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-12-28 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2020-12-10 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-11-11 | Eingeleitet | Berenberg | Hold |
| 2020-06-17 | Eingeleitet | BTIG Research | Buy |
| 2020-02-04 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2019-11-12 | Bestätigt | H.C. Wainwright | Buy |
| 2019-06-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-06-05 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2019-04-05 | Eingeleitet | Janney | Buy |
| 2019-01-30 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-10-29 | Eingeleitet | Citigroup | Neutral |
| 2018-08-17 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2017-10-06 | Fortgesetzt | Goldman | Neutral |
| 2017-09-13 | Bestätigt | Chardan Capital Markets | Buy |
| 2017-08-10 | Bestätigt | Chardan Capital Markets | Buy |
| 2017-01-24 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2016-05-18 | Eingeleitet | BofA/Merrill | Buy |
| 2016-04-14 | Eingeleitet | Robert W. Baird | Neutral |
| 2016-04-12 | Bestätigt | Chardan Capital Markets | Buy |
| 2015-09-16 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2015-06-16 | Bestätigt | Chardan Capital Markets | Buy |
Alle ansehen
Amicus Therapeutics Inc Aktie (FOLD) Neueste Nachrichten
Institution Moves: Can Amicus Therapeutics Inc expand its profit marginsEarnings Overview Summary & Capital Efficient Trading Techniques - baoquankhu1.vn
Amicus Therapeutics Announces Full-Year 2025 Financial Results and Corporate Updates - ADVFN
Amicus Therapeutics Hits New 52-Week High of $14.47 - Markets Mojo
How does Amicus Therapeutics Inc score in quality rankings2026 Biggest Moves & Community Shared Stock Ideas - baoquankhu1.vn
Patterns Watch: Will Amicus Therapeutics Inc benefit from geopolitical trendsPortfolio Gains Summary & Consistent Growth Equity Picks - baoquankhu1.vn
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
(FOLD) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Amicus Therapeutics Hits New 52-Week High of $14.48 - Markets Mojo
Panic Selling: Is Amicus Therapeutics Inc showing insider buyingWeekly Market Outlook & Daily Technical Forecast Reports - baoquankhu1.vn
Gap Down: Will Amicus Therapeutics Inc benefit from geopolitical trendsBuy Signal & Reliable Momentum Entry Alerts - baoquankhu1.vn
Will Amicus Therapeutics Inc benefit from geopolitical trends2026 Dividend Review & Fast Gain Stock Trading Tips - baoquankhu1.vn
Amicus Therapeutics stock hits 52-week high at 14.46 USD By Investing.com - Investing.com Australia
Amicus Therapeutics stock hits 52-week high at 14.46 USD - Investing.com
FOLD Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Amicus Therapeutics (NASDAQ:FOLD) Hits New 1-Year HighTime to Buy? - MarketBeat
BioMarin Pharmaceutical Secures European Regulatory Approval for Amicus Therapeutics Acquisition - marketscreener.com
EU Commission OKs BioMarin's Sole Acquisition of Amicus Therapeutics - marketscreener.com
Capricorn Fund Managers Ltd Invests $3 Million in Amicus Therapeutics, Inc. $FOLD - MarketBeat
FOLD Technical Analysis & Stock Price Forecast - intellectia.ai
Amicus Therapeutics stock hits 52-week high at $14.44 By Investing.com - Investing.com South Africa
Amicus Therapeutics stock hits 52-week high at $14.44 - Investing.com
EPS Watch: Is Amicus Therapeutics Inc in a bullish channelMarket Sentiment Report & Weekly High Return Stock Opportunities - baoquankhu1.vn
Amicus Therapeutics (NASDAQ:FOLD) Reaches New 1-Year HighStill a Buy? - MarketBeat
Assessing Amicus Therapeutics (FOLD) Valuation After A Strong 71% One Year Total Return - Yahoo Finance
210,800 Shares in Amicus Therapeutics, Inc. $FOLD Acquired by CIBRA Capital Ltd - MarketBeat
FOLD PE Ratio & Valuation, Is FOLD Overvalued - intellectia.ai
Recap Report: What is the long term forecast for Amicus Therapeutics Inc stockQuarterly Market Review & Free Daily Entry Point Trade Alerts - baoquankhu1.vn
Vanguard disaggregates holdings, reports 0% in Amicus (NASDAQ: FOLD) - Stock Titan
JPMorgan Chase & Co. Sells 94,105 Shares of Amicus Therapeutics, Inc. $FOLD - MarketBeat
ETFs investiert in Amicus Therapeutics, Inc.-Aktien - TradingView
Morgan Stanley Upgrades Amicus (FOLD) on IP Strength and Pipeline Expansion - MSN
Amicus Therapeutics (NASDAQ:FOLD) Hits New 52-Week HighWhat's Next? - MarketBeat
Amicus Therapeutics stock hits 52-week high at 14.39 USD By Investing.com - Investing.com Canada
Amicus Therapeutics stock hits 52-week high at 14.39 USD - Investing.com
Hudson Bay Capital Management LP Cuts Position in Amicus Therapeutics, Inc. $FOLD - MarketBeat
Amicus Therapeutics, Inc.(NasdaqGM: FOLD) dropped from NASDAQ Biotechnology Index - marketscreener.com
FOLD Should I Buy - Intellectia AI
872,411 Shares in Amicus Therapeutics, Inc. $FOLD Acquired by Ion Asset Management Ltd. - MarketBeat
Iron Triangle Partners LP Takes Position in Amicus Therapeutics, Inc. $FOLD - MarketBeat
BioMarin to acquire rare disease drug developer Amicus for $4.8B - MSN
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Assessing Amicus Therapeutics (FOLD) Valuation After Recent Share Price Momentum And DCF Upside - Yahoo Finance
Amicus Therapeutics stock hits 52-week high at 14.38 USD By Investing.com - Investing.com Nigeria
Elevation Point Wealth Partners LLC Makes New Investment in Amicus Therapeutics, Inc. $FOLD - MarketBeat
Assessing Amicus Therapeutics (FOLD) Valuation After Strong Recent Share Price Momentum - simplywall.st
Amicus Therapeutics, Inc. $FOLD Shares Sold by Prosight Management LP - MarketBeat
Avoro Capital Advisors LLC Decreases Stock Holdings in Amicus Therapeutics, Inc. $FOLD - MarketBeat
Assessing Amicus Therapeutics (FOLD) After Strong One Year Share Price Performance - simplywall.st
Amicus Therapeutics stock hits 52-week high at 14.38 USD - Investing.com India
Finanzdaten der Amicus Therapeutics Inc-Aktie (FOLD)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.69%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):